TC Biopharm PLC, a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announced that it has successfully registered the UK trademark "CryoTC", for the Company's proprietary process for freezing and thawing of its lead oncology product, OmnImmune.
CryoTR is TC BioPharm's unique process of cryopreservation, which is performed in a controlled rate freezer using an optimized protocol. OmnImmune is an allogeneic unmodified cell therapy consisting of activated and expanded gamma delta T cells. OmnImmune comprises GDT cells sourced from healthy donors, activated and expanded in large numbers before being purified formulated, and cryopreserved for subsequent thawing and infusion into patients.
"Being the first gamma delta cell therapy company with a frozen/thawed product in the clinic is yet another milestone achieved by TCBP," said Bryan Kobel, CEO of TC BioPharm. "This novel freeze-thaw process truly establishes OmnImmune an 'off the shelf' cell therapy, allowing us to campaign manufacture, ship and store the product around the world for the potential treatment of AML and other blood cancers. Given the multiple development trials and programs we are advancing with OmnImmune, we are pleased to have this trademark contribute to our brand protection and continue to validate our position at the forefront of innovation in the gamma delta vertical."
